BU-NOT-SET
- Recipharm centres its strategic, commercial and operational decision-making in Switzerland, reflecting its evolution into a more integrated global organisation built to serve customers across its global network
- Recipharm Group AG serves as the Group’s new headquarters and central management entity
Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the relocation of its Group Headquarters from Sweden to Switzerland. The move centres the Group's strategic, commercial and operational decision-making in Switzerland, reflecting Recipharm's evolution into a more integrated global organisation built to deliver seamless support for customers across its global network. It also aligns the Group's legal structure with its operating model. As one of the world's leading pharmaceutical and biotechnology hubs, Switzerland provides an ideal base for Recipharm, combining close proximity to customers with access to one of the world's most advanced life sciences ecosystems.
To meet customers' demand for integrated, end-to-end solutions, Recipharm has transformed over recent years into a leading, integrated global organisation, with strategic decision-making being conducted from Switzerland. This shift, supported by continued investment in digital and AI-enabled technologies, has enabled the Group to leverage its global scale more effectively and unlock network-wide synergies, while supporting sustained investment across its global network. Recent examples include expanded high potency oral solid dose manufacturing, additional sterile fill and finish capacity in the US, and new product development capabilities, each strengthening the Group's ability to support customers from early development through to commercial supply.
Greg Behar, CEO of Recipharm, said: "Our new Group Headquarters in Switzerland takes Recipharm to new heights, placing our strategic, commercial and operational leadership at the heart of the pharmaceutical and life sciences industry. It gives us a stronger base to build long-term partnerships with our customers, and ultimately to serve the patients who depend on us every day."
Recipharm Group AG (Switzerland) now serves as the Group's headquarters and central management entity. The headquarters change does not affect the Group's operations, people or customer-facing teams.
Ends)
For more information
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,500 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.
Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Headquartered in Switzerland, it operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.
For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com
Media contact:
Guenaelle Holloway, Head of marketing and communications
[email protected]
+44 7730 303 708